Compare CVS Health Corp (CVS) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs State Street SPDR S&P Homebuilders ETF — how do they compare? CVS Health Corp trades at $94.04 (market cap $119.58B), while State Street SPDR S&P Homebuilders ETF trades at $108.74. The key difference: CVS Health Corp pays a 2.84% dividend while State Street SPDR S&P Homebuilders ETF pays none, and CVS Health Corp is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| CVS | XHB | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $121.36 |
52-Week Low | $65.51 | $94.86 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.
The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.
XHB trades at $108.22, down slightly by 0.02% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights mixed housing data, including a 1.6% rise in new home sales in June 2026 (Census Bureau, 2026-07-24) but a 2.4% drop in existing home sales (CNBC, 2026-07-09). The ETF benefits from a new housing affordability law (Zacks Investment Research, 2026-07-13), though financial ratios are unavailable.
Outlook is cautiously optimistic due to policy support and technical strength, but risks include high mortgage rates and volatile home sales. Investors should weigh bullish momentum against macroeconomic headwinds in the housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
